Pulsenmore Set to Reveal 2025 Financials: A Look at the Future of Home Ultrasound
Pulsenmore Ltd. (NASDAQ, TASE: PLSM) has announced it will release its full year 2025 financial results on March 30, 2026, at 8:30 a.m. EST. The company, a pioneer in home ultrasound technology, will host a conference call and webcast to discuss the results, business highlights, and recent progress. This announcement comes as the remote patient monitoring and telehealth sectors continue to experience significant growth.
The Rise of Remote Ultrasound: A Paradigm Shift in Prenatal Care
Pulsenmore’s core offering – a handheld ultrasound cradle that connects to a patient’s smartphone and a clinician dashboard for remote review – positions the company at the forefront of a growing trend. Traditionally, prenatal care has relied heavily on in-person visits. However, advancements in technology are enabling more convenient and accessible options for expectant mothers. This shift is particularly important for those in rural areas or with limited access to healthcare facilities.
The company’s technology allows for physician-directed, technology-enabled solutions, broadening access to prenatal care. Pulsenmore’s executive leadership, including Chairman Jonathan Adereth, CEO Dr. Elazar Sonnenschein, CFO Eran Hirsh, and VP of Marketing Mira Altmark-Sofer, will be available on the call to discuss the company’s performance and future strategies.
Financial Performance and Market Context
As of March 17, 2026, Pulsenmore’s stock (PLSM) was trading at $4.20, down 2.33% from the previous day’s close. Year-to-date, the stock has experienced a significant decline of 55.56%. However, the company’s market capitalization is $27.312M. The Nasdaq search results indicate that real-time data is available, highlighting the dynamic nature of the stock market.
The company’s focus on remote clinical diagnosis and screening in Israel and Europe aligns with the increasing demand for telehealth solutions globally. The FDA De Novo authorization and Nasdaq listing are key milestones that demonstrate Pulsenmore’s commitment to expanding its reach and strengthening its presence in the U.S. Market.
Looking Ahead: Potential Growth Drivers
Several factors could drive Pulsenmore’s future growth. Increased adoption of telehealth, particularly in the maternal health space, is a major catalyst. Further expansion into new geographic markets and the development of new applications for its ultrasound technology could as well contribute to revenue growth. The company’s ability to secure partnerships with healthcare providers and insurance companies will be crucial for widespread adoption.
Did you recognize? Pulsenmore was incorporated in 2014 and is based in Omer, Israel, employing 58 full-time employees.
Potential Risks and Challenges
Pulsenmore’s forward-looking statements acknowledge several risks, including its limited operating history, capital requirements, and reliance on intellectual property protection. The company also faces challenges related to regulatory compliance, market acceptance, and competition. Political and economic instability in the Middle East could also pose a risk to its business.
FAQ
Q: When will Pulsenmore release its 2025 financial results?
A: March 30, 2026, at 8:30 a.m. EST.
Q: How can I access the conference call and webcast?
A: The webcast link is: https://teams.microsoft.com/meet/3845461353556?p=fcIpXc4mErwEAqo3Ir. A replay will be available on the company’s Investor Relations website.
Q: What does Pulsenmore do?
A: Pulsenmore develops and provides self-scan ultrasound devices for remote clinical diagnosis and screening.
Q: Where is Pulsenmore based?
A: Omer, Israel.
Pro Tip: Maintain an eye on Pulsenmore’s Investor Relations website (https://pulsenmore.com/investor_relations/) for the latest updates and financial reports.
For more information, visit www.pulsenmore.com.
Contact:
Miri Segal-Schari
MS-IR LLC
[email protected]
